Venom conjugated polylactide applied as biocompatible material for passive and active immunotherapy against scorpion envenomation - RIIP - Réseau International des Instituts Pasteur Accéder directement au contenu
Article Dans Une Revue Vaccine Année : 2016

Venom conjugated polylactide applied as biocompatible material for passive and active immunotherapy against scorpion envenomation

Résumé

Scorpion envenoming represents a public health issue in subtropical regions of the world. Treatment and prevention need to promote antitoxin immunity. Preserving antigenic presentation while removing toxin effect remains a major challenge in toxin vaccine development. Among particulate adjuvant, particles prepared with poly (D,L-lactide) polymer are the most extensively investigated due to their excellent biocompatibility and biodegradability. The aim of this study is to develop surfactant-free PLA nanoparticles that safely deliver venom toxic fraction to enhance specific immune response. PLA nanoparticles are coated with AahG50 (AahG50/PLA) and BotG50 (BotG50/PLA): a toxic fraction purified from Androctonus australis hector and Buthus occitanus tunetanus venoms, respectively. Residual toxicities are evaluated following injections of PLA-containing high doses of AahG50 (or BotG50). Immunization trials are performed with the detoxified fraction administered alone without adjuvant. A comparative study of the effect of Freund is also included. The neutralizing capacity of sera is determined in naive mice. Six months later, immunized mice are challenged subcutaneously with increased doses of AahG50. Subcutaneous lethal dose 50 (LD50) of AahG50 and BotG50 is of 575 μg/kg and 1300 μg/kg respectively. By comparison, BotG50/PLA is totally innocuous while 50% of tested mice survive 2875 μg AahG50/kg. Alhydrogel and Freund are not able to detoxify such a high dose. Cross-antigenicity between particulate and soluble fraction is also, ensured. AahG50/PLA and BotG50/PLA induce high antibody levels in mice serum. The neutralizing capacity per mL of anti-venom was 258 μg/mL and 186 μg/mL calculated for anti-AahG50/PLA and anti-BotG50/PLA sera, respectively. Animals immunized with AahG50/PLA are protected against AahG50 injected dose of 3162 μg/kg as opposed all non-immunized mice died at this dose. We find that the detoxification approach based PLA nanoparticles, benefit the immunogenicity and protective efficacy of venom immunogen.
Fichier non déposé

Dates et versions

pasteur-01471735 , version 1 (20-02-2017)

Identifiants

Citer

Sana Ayari-Riabi, Thomas Trimaille, Kamel Mabrouk, Denis Bertin, Didier Gigmes, et al.. Venom conjugated polylactide applied as biocompatible material for passive and active immunotherapy against scorpion envenomation. Vaccine, 2016, 34 (15), pp.1810 - 1815. ⟨10.1016/j.vaccine.2016.02.030⟩. ⟨pasteur-01471735⟩
77 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More